Pfizer head is Sephardi Jew born in Thessaloniki

The pharmaceutical giant Pfizer has become a household name as  a manufacturer of the  COVID-19 vaccine. But how many know that its CEO is a Sephardi Jew, Albert Bourla? The Jewish Voice reports (with thanks: Ambrosine):

Albert Bourla

As the announcement
of a vaccine that is 90% effective in preventing the
novel coronavirus has dominated the headlines and
given hope to people in every corner of the globe, we
pause at this juncture to pay tribute to Albert
Bourla, the chairman and CEO of pharmaceutical giant
Pfizer.

Founded in 1849 in
New York City by Charles Pfizer, the eponymously named
pharmaceutical company is one of the world’s largest
of its kind and it ranked 57 on the 2018 Fortune 500
list of the largest United States corporations by
total revenue. Pfizer develops and produces medicines
and vaccines for a wide range of medical disciplines,
including immunology, oncology, cardiology,
endocrinology, and neurology. Its products include the
blockbuster drug Lipitor (atorvastatin), used to lower
LDL blood cholesterol; Lyrica (pregabalin) for
neuropathic pain and fibromyalgia; Diflucan
(fluconazole), an oral antifungal medication;
Zithromax (azithromycin), an antibiotic; Viagra
(sildenafil) for erectile dysfunction; and Celebrex
(also Celebra, celecoxib), an anti-inflammatory drug.

Currently, Pfizer
is under the dynamic and innovative leadership of a
man who came from humble beginnings and who rose to
prominence in the medical field through his remarkable
diligence and his tireless desire to help people.

Born in October of
1961 in Thessaloniki, Greece, Albert Bourla was raised
in a Sephardic Jewish family. Bourla is a Doctor of
Veterinary Medicine and holds a Ph.D. in the
Biotechnology of Reproduction from the Veterinary
School of Aristotle University. He left Greece with
his wife when he was 34 and since then he has lived in
seven different cities, in four different countries.

In 2020, he was
ranked as America’s top CEO in the Pharmaceuticals
sector by Institutional Investor magazine. He is on
the executive committee of The Partnership for New
York City, a director on multiple boards – Pfizer,
Inc., The Pfizer Foundation, PhRMA, and Catalyst – and
a Trustee of the United States Council for
International Business. In addition, Bourla is a
member of the Business Roundtable and the Business
Council.

Bourla began his
career at Pfizer in 1993 in the Animal Health Division
as Technical Director of Greece. He held positions of
increasing responsibility within Animal Health across
Europe, before moving to Pfizer’s New York Global
Headquarters in 2001. From there, Bourla went on to
assume a succession of leadership roles within the
Animal Health Division, including US Group Marketing
Director (2001-2004), Vice President of Business
Development and New Products Marketing (2004-2006),
and Area President of Animal Health Europe, Africa and
the Middle East (2006-2009). In 2009, he assumed
additional responsibilities for the Asia and Pacific
regions.

From 2010-2013,
Bourla was President and General Manager of Pfizer’s
Established Products business from 2010-2013, leading
the development and implementation of strategies and
tactics related to Pfizer’s off-patent portfolio,
(including legacy brands and generics).

From January 2014
to January 2016, Bourla served as Group President of
Pfizer’s Global Vaccines, Oncology, and Consumer
Healthcare business, where he was instrumental in
building a strong and competitive position in oncology
and expanding the Company’s leadership in vaccines.

Previously, from
February 2016 to December 2017, Bourla served as Group
President of Pfizer Innovative Health, which comprised
the Consumer Healthcare, Inflammation &
Immunology, Internal Medicine, Oncology, Rare Disease
and Vaccines business groups. In addition, he created
the Patient and Health Impact Group, dedicated to
developing solutions for increasing patient access,
demonstrating the value of Pfizer’s medicines, and
ensuring broader business model innovation.

Bourla became
Pfizer’s chief operating officer (COO) on January 1,
2018, overseeing the company’s drug development,
manufacturing, sales, and strategy, as stated in a
Wikipedia profile. He restructured Pfizer and spun-off
the consumer health care business during his tenure as
COO. He was promoted to the chief executive officer
(CEO) role in October 2018, effective January 1, 2019,
succeeding Ian Read.

Read article in full

Moderna’s chief medical officer Tal Zaks is Jewish too (Atlanta Jewish Times)

Leave a Reply

Your email address will not be published.

About

This website is dedicated to preserving the memory of the near-extinct Jewish communities, of the Middle East and North Africa, documenting the stories of the Jewish refugees and their current struggle for recognition and restitution.

Point of No Return

Jewish Refugees from Arab and Muslim Countries

One-stop blog on the Middle East's
forgotten Jewish refugees - updated daily.